Based on the findings of the study, which showed an increased risk of cancer in Belviq users, the FDA decided to ask the producers of Belviq to voluntarily recall the drug from the market. The manufacturer agreed to the voluntarily recall request.
In their official website statement regarding the voluntarily recall request of Belviq, the FDA stated:
“We are taking this action because we believe that the risks of lorcaserin outweigh its benefits based on our completed review of results from a randomized clinical trial assessing safety.”
The recall was published on February 13th, 2020, approximately one month after the FDA indicated that there may be a higher cancer risk associated with Belviq. The recall is still effective and is estimated not to be reversed.